on Affluent Medical (isin : FR0013333077)
Affluent Medical Rebrands as CARVOLIX
Affluent Medical, a French medtech company specializing in AI-driven medical technologies, has officially rebranded as CARVOLIX following the completion of acquisitions of Caranx Medical and Artedrone. This strategic consolidation aims to leverage advanced technology in autonomous mini-robots and biomimetic implants for cardiology and stroke treatments.
The company completed a €10m initial financing tranche supported by Truffle Capital and Edwards Lifesciences, providing a significant premium above the last closing share price. This funding is pivotal to extend CARVOLIX's cash position to May 2026 and support its product development and commercialization efforts.
CARVOLIX aims to address unmet medical needs in cardiac valve replacement and stroke treatment, focusing on innovations like the FDA-approved TAVIPILOT software, expected to boost the company's position across Europe, the US, Middle East, and Asia.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Affluent Medical news